Patents
Sitemap › C12 - Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or genetic engineering › C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media › C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637)
12/2003
12/31/2003CA2489052A1 Infectious cdna of an approved vaccine strain of measles virus, use for immunogenic compositions
12/31/2003CA2488856A1 Packaged virus-like particles for use as adjuvants: method of preparation and use
12/31/2003CA2478508A1 Stable adenoviral vectors and methods for propagation thereof
12/30/2003US6670199 Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
12/30/2003US6670188 Packaging systems for human recombinant adenovirus to be used in gene therapy
12/30/2003US6670176 Adeno-associated virus capable of expressing factor IX protein and cells comprising the same
12/30/2003US6670167 Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
12/30/2003US6670114 Screening for molecules which modulate the binding between HCV and human apolipoprotein B
12/30/2003US6669943 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
12/30/2003US6669942 Defective adenoviruses having a genome that includes a first recombinant DNA containing a therapeutic gene and a second rcombinant DNA containing an immunoprotective gene
12/30/2003US6669936 Gene therapy
12/30/2003CA2128421C Insecticidal toxins derived from funnel web (atrax or hadronyche) spiders
12/25/2003US20030236396 Secretory signal sequences and uses thereof
12/25/2003US20030236390 Materials for the production of nanometer structures and use thereof
12/25/2003US20030235899 Catalytic domain of the human effector cell cycle checkpoint protein kinase Chk1 materials and methods for identification of inhibitors thereof
12/25/2003US20030235835 Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
12/24/2003WO2003106665A1 Method for culturing hvc virus in vitro
12/24/2003WO2003106664A1 Process for preparing an adenovirus-containing preparation
12/24/2003WO2003105875A1 Immunostimulator having antineoplastic action and method for producing said immunostimulator
12/24/2003WO2003078455A3 Virus like particle from papillomavirus and their use in vaccine
12/24/2003WO2003077942A3 Virus-like particles of human papillomavirus
12/24/2003WO2003054210A3 Regulated nucleic acid expression system
12/24/2003WO2003000888A3 Method for separating bacterial cells and cell components
12/24/2003CN1462804A Filtering out non essential segment in copying adenovirus of birds, and its gene engineering products
12/24/2003CN1462635A Microzyme vaccine and bacterin for SARS epidemical tissue and its manufacturing method
12/24/2003CA2489292A1 Vectors for expression of hml-2 polypeptides
12/23/2003US6667295 DNA vaccine against feline immunodeficiency virus
12/18/2003WO2003104797A1 Methods and apparatus for harvesting vaccine from eggs
12/18/2003WO2003104476A2 Assay to detect replication competent viruses
12/18/2003WO2003104469A1 Adenovirus vector
12/18/2003WO2003103605A2 Flexible vaccine assembly and vaccine delivery platform
12/18/2003WO2003103578A2 Bacteriophage and enzymes lytic to salmonellae
12/18/2003WO2003103571A2 Flavivirus vaccines
12/18/2003WO2003103390A1 Sterilization, stabilization and preservation of functional biologics
12/18/2003WO2003054160A3 Cell lines with latent immunodeficiency virus and methods of use thereof
12/18/2003WO2003039477A9 Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding
12/18/2003WO2003016540A3 Humanised baculovirus
12/18/2003WO2003014342A3 Identification of a dna variant associated with adult type hypolactasia
12/18/2003WO2002099035A3 Chimeric alphavirus replicon particles
12/18/2003WO2002097034A3 Antibodies and antigens of hiv viremia controllers
12/18/2003WO2002086059A3 Recombinant vaccinia viral vectors
12/18/2003US20030232969 Method for separating off viruses from a protein solution by means of nanofiltration
12/18/2003US20030232745 Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
12/18/2003US20030232409 Genetically engineered swine cell for use as models in cancer treatment and diagnosis
12/18/2003US20030232326 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
12/18/2003US20030232061 For therapy of respiratory tract infection in a mammal
12/18/2003US20030232060 Administering an immunizing composition comprising: a carrier; a plasmid encoding an attenuated, doxycycline-inducible proviral molecular clone of the human immunodeficiency virus type 1 (HIV-1), to induce viral expression of the plasmid
12/18/2003US20030232058 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
12/18/2003US20030232036 Alphavirus RNA replicon systems
12/18/2003CA2488778A1 Assay to detect replication competent viruses
12/18/2003CA2487826A1 Sterilization, stabilization and preservation of functional biologics
12/18/2003CA2486118A1 Flexible vaccine assembly and vaccine delivery platform
12/18/2003CA2473321A1 Flavivirus vaccines
12/17/2003EP1371730A2 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
12/17/2003EP1371723A1 Process for preparing an adenovirus-containing preparation
12/17/2003EP1370668A2 Leporipox-based vector vaccines
12/17/2003EP1370666A2 Genetic immunisation against cervical carcinoma
12/17/2003EP1370643A1 Method of extracting virus from cell culture
12/17/2003EP1370283A2 Prevention of recurrent viral disease
12/17/2003EP0956349B1 Synthetic hpv16 virus-like particles
12/17/2003EP0792363B1 Novel pesticidal proteins and strains
12/17/2003CN1461805A Structure of recombination herpes simplex virus and its use
12/16/2003US6664370 Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
12/16/2003US6664099 Method for the preservation of viruses and mycoplasma
12/16/2003US6664090 Carboxylesterase nucleic acid molecules, proteins and uses thereof
12/16/2003US6664066 Modified Morbillivirus V proteins
12/16/2003US6664063 Methods for separating,fractionating and analyzing gene of virus existing in hydrosphere
12/16/2003US6664050 Assaying a sample using an antibody specific to an adenovirus type 36p to test for the presence of the adenovirus; thus testing whether the person has been or is infected with adenovirus type 36p
12/16/2003US6664041 Method for preparing a viral extract containing HIV-II RNA
12/16/2003US6663872 Immune response
12/16/2003US6663871 Non-replicating or replication- impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition, malaria
12/16/2003CA2072627C Recombinant herpes simplex viruses vaccines and methods
12/11/2003WO2003102157A2 Synthetic antibody phage libraries
12/11/2003WO2003102021A2 Cotton rat lung cells for virus culture
12/11/2003WO2003101397A2 Tetravalent dengue vaccines
12/11/2003WO2003101396A2 Helper virus-free herpesvirus amplicon particles and uses thereof
12/11/2003WO2003080823A3 Bacteriophages useful for therapy and prophylaxis of bacterial infections
12/11/2003WO2003054212A3 A method and compositions for conferring viral immunity and reversing viral pathogenesis via strategic infection with a theravirus thereby providing genomic integration of genetically engineered, replication incompetent, integrating viral dna
12/11/2003WO2003048348A3 Production of viruses, viral isolates and vaccines
12/11/2003WO2003023042A9 Recombinant mva capable of expressing structural hcv antigens
12/11/2003WO2002096940A3 Attenuated very virulent infectious bursal disease virus
12/11/2003US20030229208 Humanized immunoglobulins
12/11/2003US20030228696 Novel insect cell line
12/11/2003US20030228679 Compositions and methods for increasing plant growth by inoculation with bacillus strains
12/11/2003US20030228623 For rapid production of diverse populations of selectable compounds as well as ready selection from such populations of small molecules attached to display peptides that bind target molecules or have desired activities (e.g. antibiotics); drugs
12/11/2003US20030228576 Nucleotide sequence coding for a cleaving enzyme; can use in conjuction with substrate to produce toxins which impair abnormal cell growth; antitumor agents
12/11/2003US20030228285 Bipartite T-cell factor (Tcf)-responsive promoter
12/11/2003US20030228282 Genetic engineered polypeptide; inserted into cell; blood disorders
12/11/2003US20030227613 Methods and apparatus for harvesting vaccine from eggs
12/11/2003CA2488441A1 Synthetic antibody phage libraries
12/11/2003CA2487897A1 Helper virus-free herpesvirus amplicon particles and uses thereof
12/10/2003EP1369427A2 HIV-3 retrovirus strains and their use
12/10/2003EP1368459A2 Influenza viruses with enhanced transcriptional and replicational capacities
12/10/2003EP1368058A2 Viral reporter particles
12/10/2003EP1144420B1 Sulfated phosphatidylinositols, their preparation and use
12/10/2003EP0996735B1 Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
12/10/2003EP0958371B1 Cytopathic viruses for therapy and prophylaxis of neoplasia
12/10/2003CN1130227C Viral agent associated with mystery swine disease
12/09/2003US6660514 Binding to a first matrix comprising heparin; eluting; contacting with an iodixanol gradient
12/09/2003US6660513 Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142
1 ... 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 ... 267